Pasaje Artístico La Mariposa

76 p.

La mise en valeur de l'archéologie sur la côte nord du Pérou : le cas de Chan Chan et de Huacas de Moche.

Notre mémoire porte sur la mise en valeur du patrimoine archéologique sur la côte nord du Pérou. À partir de deux études de cas, Chan Chan et Huacas de Moche, nous cherchons à faire ressortir différentes approches de mise en valeur au complexe archéologique et d’exposition au musée de site. La cité de Chan Chan aurait été la capitale de l’Empire chimor (900 à 1476 ap. J.C.) et utilisée à titre de siège pour le gouvernement, de résidence, de centre administratif et de centre religieux. Le complexe de Huaca del Sol y de la Luna aurait été la capitale de la civilisation moche (100 av. J.C. à 700 ap. J.C.) à son apogée. Il représente l’un des plus anciens centre urbain-cérémonial de la côte nord du Pérou. Le cas du Musée de site de Chan Chan présente un modèle muséographique des années 1990, tandis que le cas du Musée de site de Huacas de Moche propose une approche puisant ses concepts dans la nouvelle muséologie (2010). D’autre part, ces modèles de gestion, l’un issu du secteur public (Chan Chan) et l’autre (Huacas de Moche) émanant d’une gestion mixte ont une influence sur la manière de présenter l’archéologie au public. Le premier chapitre aborde l’histoire du développement de l’archéologie, des musées et du tourisme au Pérou. La deuxième partie de ce chapitre traite des questions liées à l’herméneutique de la culture matérielle, des questions esthétiques et de l’architecture précolombienne, ainsi que des approches de médiation. Le deuxième chapitre met en parallèle l’analyse du circuit de visite du complexe archéologique de Chan Chan et celui de Huacas de Moche. Le troisième chapitre présente l’analyse de la mise en exposition des musées de site des deux études de cas et des liens créés avec leur site archéologique. Le quatrième chapitre porte sur les formes de financement des projets de fouilles, de conservation, de restauration et de mise en valeur de l’archéologie, ainsi que des stratégies utilisées pour sa diffusion et sa mise en tourisme. Enfin, la dernière section du quatrième chapitre traite des différents moyens utilisés par chacun des complexes archéologiques et leurs musées pour intégrer la communauté locale aux projets de recherche et de mise en valeur archéologique.

La mise en valeur de l'archéologie sur la côte nord du Pérou : le cas de Chan Chan et de Huacas de Moche

Notre mémoire porte sur la mise en valeur du patrimoine archéologique sur la côte nord du Pérou. À partir de deux études de cas, Chan Chan et Huacas de Moche, nous cherchons à faire ressortir différentes approches de mise en valeur au complexe archéologique et d’exposition au musée de site. La cité de Chan Chan aurait été la capitale de l’Empire chimor (900 à 1476 ap. J.C.) et utilisée à titre de siège pour le gouvernement, de résidence, de centre administratif et de centre religieux. Le complexe de Huaca del Sol y de la Luna aurait été la capitale de la civilisation moche (100 av. J.C. à 700 ap. J.C.) à son apogée. Il représente l’un des plus anciens centre urbain-cérémonial de la côte nord du Pérou. Le cas du Musée de site de Chan Chan présente un modèle muséographique des années 1990, tandis que le cas du Musée de site de Huacas de Moche propose une approche puisant ses concepts dans la nouvelle muséologie (2010). D’autre part, ces modèles de gestion, l’un issu du secteur public (Chan Chan) et l’autre (Huacas de Moche) émanant d’une gestion mixte ont une influence sur la manière de présenter l’archéologie au public. Le premier chapitre aborde l’histoire du développement de l’archéologie, des musées et du tourisme au Pérou. La deuxième partie de ce chapitre traite des questions liées à l’herméneutique de la culture matérielle, des questions esthétiques et de l’architecture précolombienne, ainsi que des approches de médiation. Le deuxième chapitre met en parallèle l’analyse du circuit de visite du complexe archéologique de Chan Chan et celui de Huacas de Moche. Le troisième chapitre présente l’analyse de la mise en exposition des musées de site des deux études de cas et des liens créés avec leur site archéologique. Le quatrième chapitre porte sur les formes de financement des projets de fouilles, de conservation, de restauration et de mise en valeur de l’archéologie, ainsi que des stratégies utilisées pour sa diffusion et sa mise en tourisme. Enfin, la dernière section du quatrième chapitre traite des différents moyens utilisés par chacun des complexes archéologiques et leurs musées pour intégrer la communauté locale aux projets de recherche et de mise en valeur archéologique.

Financial & business Assistance Bulletin, January 2013

This as a year of continuity and ongoing success for the Financial and Business Assistance (FABA) Section. Whether we were providing financial and technical assistance services through our existing programs or new ones, we worked to create public-private partnerships that have a positive impact to Iowa’s economy and environment.

El Diálogo Competitivo como instrumento para la maduración de proyectos de infraestructura vial

En Colombia, mediante la Ley 1508 de 2102, se estableció el régimen jurídico de las Asociaciones Público Privadas (APP) y con la aprobación de la Ley 1682 de 2013, se regularon los proyectos de infraestructura de transporte. Con la presente tesis se pretende demostrar la figura del Diálogo Competitivo como procedimiento incompleto e insuficiente, apropiado así por nuestro régimen jurídico en la Ley de APP, visto desde la perspectiva de la Unión Europea, especialmente de los modelos español, inglés y francés, porque carece de la mayoría de sus elementos característicos. Posteriormente se realiza una crítica al Diálogo Competitivo colombiano desde la perspectiva de la Unión Europea, ya que se evidencia en la figura interna su precariedad frente a un procedimiento debidamente definido y organizado como el de la Unión Europea. Entre las instituciones jurídicas adoptadas por la Ley de APP, se encuentra el Diálogo Competitivo, que es un procedimiento, verificado en la etapa de estructuración de los contratos APP de iniciativa pública, cuyos antecedentes registran el mayor reconocimiento internacional en la Unión Europea (UE). Ésta introdujo esa figura a su régimen jurídico, a través de la Directiva 2004/18/CE, a su vez derogada por la Directiva 2014/24/UCE. La tesis culmina con una serie de conclusiones y recomendaciones que se estiman útiles para repensar y reestructurar el Diálogo Competitivo en los proyectos de infraestructura vial en Colombia, tarea que le corresponde al Congreso Nacional, pues así lo ha dispuesta la jurisprudencia del Consejo de Estado.

Partnership in the arts : public and private support of cultural activities in the San Francisco Bay area /

Mode of access: Internet.

Turing and the Trans-Pacific Partnership: Intellectual Property, Public Health, and Access to Essential Medicines

A recent controversy in the United States over drug pricing by Turing Pharmaceuticals AG has raised larger issues in respect of intellectual property, access to medicines, and the Trans-Pacific Partnership (TPP). In August 2015, Turing Pharmaceuticals AG – a private biopharmaceutical company with offices in New York, the United States, and Zug, Switzerland - acquired the exclusive marketing rights to Daraprim in the United States from Impax Laboratories Incorporated. Martin Shkreli, Turing’s Founder and Chief Executive Officer, maintained: “The acquisition of Daraprim and our toxoplasmosis research program are significant steps along Turing’s path of bringing novel medications to patients with serious disorders, some of whom often go undiagnosed and untreated.” He emphasised: “We intend to invest in the development of new drug candidates that we hope will yield an even better clinical profile, and also plan to launch an educational effort to help raise awareness and improve diagnosis for patients with toxoplasmosis.” In September 2015, there was much public controversy over the decision of Martin Shkreli to raise the price of a 62 year old drug, Daraprim, from $US13.50 to $US750 a pill. The drug is particularly useful in respect to the treatment and prevention of malaria, and in the treatment of infections in individuals with HIV/AIDS. Daraprim is listed on the World Health Organization’s (WHO) List of Essential Medicines. In the face of much criticism, Martin Shkreli has said that he will reduce the price of Daraprim. He observed: “We've agreed to lower the price on Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.” He maintained: “We think these changes will be welcomed.” However, he has been vague and ambiguous about the nature of the commitment. Notably, the lobby group, Pharmaceutical Research and Manufacturers of America (PhARMA), disassociated itself from the claims of Turing Pharmaceuticals. The group said: “PhRMA members have a long history of drug discovery and innovation that has led to increased longevity and improved lives for millions of patients.” The group noted: “Turing Pharmaceutical is not a member of PhRMA and we do not embrace either their recent actions or the conduct of their CEO.” The biotechnology peak body Biotechnology Industry Organization also sought to distance itself from Turing Pharmaceuticals. A hot topic: United States political debate about access to affordable medicines This controversy over Daraprim is unusual – given the age of drug concerned. Daraprim is not subject to patent protection. Nonetheless, there remains a monopoly in respect of the marketplace. Drug pricing is not an isolated problem. There have been many concerns about drug pricing – particularly in respect of essential medicines for HIV/AIDS, tuberculosis, and malaria. This recent controversy is part of a larger debate about access to affordable medicines. The dispute raises larger issues about healthcare, consumer rights, competition policy, and trade. The Daraprim controversy has provided impetus for law reform in the US. US Presidential Candidate Hillary Clinton commented: “Price gouging like this in this specialty drug market is outrageous.” In response to her comments, the Nasdaq Biotechnology Index fell sharply. Hillary Clinton has announced a prescription drug reform plan to protect consumers and promote innovation – while putting an end to profiteering. On her campaign site, she has emphasised that “affordable healthcare is a basic human right.” Her rival progressive candidate, Bernie Sanders, was also concerned about the price hike. He wrote a letter to Martin Shkreli, complaining about the price increase for the drug Daraprim. Sanders said: “The enormous, overnight price increase for Daraprim is just the latest in a long list of skyrocketing price increases for certain critical medications.” He has pushed for reforms to intellectual property to make medicines affordable. The TPP and intellectual property The Daraprim controversy and political debate raises further issues about the design of the TPP. The dispute highlights the dangers of extending the rights of pharmaceutical drug companies under intellectual property, investor-state dispute settlement, and drug administration. Recently, the civil society group Knowledge Ecology International published a leaked draft of the Intellectual Property Chapter of the TPP. Knowledge Ecology International Director, James Love, was concerned the text revealed that the US “continues to be the most aggressive supporter of expanded intellectual property rights for drug companies.” He was concerned that “the proposals contained in the TPP will harm consumers and in some cases block innovation.” James Love feared: “In countless ways, the Obama Administration has sought to expand and extend drug monopolies and raise drug prices.” He maintained: “The astonishing collection of proposals pandering to big drug companies make more difficult the task of ensuring access to drugs for the treatment of cancer and other diseases and conditions.” Love called for a different approach to intellectual property and trade: “Rather than focusing on more intellectual property rights for drug companies, and a death-inducing spiral of higher prices and access barriers, the trade agreement could seek new norms to expand the funding of medical research and development (R&D) as a public good, an area where the US has an admirable track record, such as the public funding of research at the National Institutes of Health (NIH) and other federal agencies.” In addition, there has been much concern about the Investment Chapter of the TPP. The investor-state dispute settlement regime would enable foreign investors to challenge government policy making, which affected their investments. In the context of healthcare, there is a worry that pharmaceutical drug companies will deploy their investor rights to challenge public health measures – such as, for instance, initiatives to curb drug pricing and profiteering. Such concerns are not merely theoretical. Eli Lilly has brought an investor action against the Canadian Government over the rejection of its drug patents under the investor-state dispute settlement regime of the North American Free Trade Agreement (NAFTA). The Health Annex to the TPP also raises worries that pharmaceutical drug companies will able to object to regulatory procedures in respect of healthcare. It is disappointing that the TPP – in the leaks that we have seen – has only limited recognition of the importance of access to essential medicines. There is a need to ensure that there are proper safeguards to provide access to essential medicines – particularly in respect of HIV/AIDs, malaria, and tuberculosis. Moreover, there must be protection against drug profiteering and price gouging in any trade agreement. There should be strong measures against the abuse of intellectual property rights. The dispute over Turing Pharmaceuticals AG and Daraprim is an important cautionary warning in respect of some of the dangers present in the secret negotiations in respect of the TPP. There is a need to preserve consumer rights, competition policy, and public health in trade negotiations over an agreement covering the Pacific Rim.

Short-term evaluation and research issues for the Job Training Partnership Act of 1982 : impact of different forms of private sector participation on client characteristics and program outcomes : final report /

"December, 1983."

Traps for the unwary : reform stories of private sector managers entering public service

The purpose of this research is to capture and interpret the stories of “outsider” managers who make the transition to the public sector. These experiences are considered in the context of efforts to shift public management culture in a direction consistent with meeting contemporary demands placed on public sector organisations. It is often noted that an important strategy for changing culture is the infusion of outsiders. Outsiders are thought to bring new perspectives that, through a dialectical process (Van de Ven 1995), create the potential for change. While there have been cross-sector comparisons (Broussine 1990; Silfvast 1994; Redman 1997), little attention has been given to the experience of those who make the transition in the context of efforts to reform public sector management culture. Not only is the infusion of private sector managers into the public sector a potential culture change strategy, it is also a personal experience for those who make the transition. Boundary crossing is typically an anxiety provoking experience (Van Maanen & Schein 1979) and the quality of this experience influences decisions to commit, engage, disengage or exit. The quality of the experience is likely to be affected by how the public organisation responds to people making this transition, that is, their investment in people processing (Saks 2007). The cost of recruitment and selection processes at middle and senior management levels warrants a greater research focus on this transition. In this paper we argue that the experiences of those who make the transition from private to public sectors has much to tell us about the traps that transition managers experience in making this change, the implications for injecting outsider managers as a strategy for achieving public management culture change, and how reform-oriented public organisations can manage the transitions of outsider managers into the public sector in order that best value might be achieved for both the individual and organisational change goals.

At work or play : a comparison of private property vehicle crashes with those occurring on public roads in north Queensland.

Objective: To define characteristics of vehicle crashes occurring on rural private property in north Queensland with an exploration of associated risk factors. Design: Descriptive analysis of private property crash data collected by the Rural and Remote Road Safety Study. Setting: Rural and remote north Queensland. Participants: A total of 305 vehicle controllers aged 16 years or over hospitalised at Atherton, Cairns, Mount Isa or Townsville for at least 24 hours as a result of a vehicle crash. Main outcome measure: A structured questionnaire completed by participants covering crash details, lifestyle and demographic characteristics, driving history, medical history, alcohol and drug use and attitudes to road use. Results: Overall, 27.9% of interviewees crashed on private property, with the highest proportion of private road crashes occurring in the North West Statistical Division (45%). Risk factors shown to be associated with private property crashes included male sex, riding off-road motorcycle or all-terrain vehicle, first-time driving at that site, lack of licence for vehicle type, recreational use and not wearing a helmet or seatbelt. Conclusions: Considerable trauma results from vehicle crashes on rural private property. These crashes are not included in most crash data sets, which are limited to public road crashes. Legislation and regulations applicable to private property vehicle use are largely focused on workplace health and safety, yet work-related crashes represent a minority of private property crashes in north Queensland.